AAVogen’s Post

View organization page for AAVogen, graphic

438 followers

This unfortunate news is far from surprising. The problem is two-fold: minimal dystrophin expression and failure to account for accumulated muscle damage. Combinatorial treatment with AVGN7 could address the latter and possibly improve the former. Interested companies should contact AAVogen. https://lnkd.in/eFabEFZQ

Nippon Shinyaku’s DMD drug fails confirmatory trial

Nippon Shinyaku’s DMD drug fails confirmatory trial

pharmaphorum.com

To view or add a comment, sign in

Explore topics